Results 211 to 220 of about 8,019,599 (294)

Crosstalk Between mTOR and NF-κB Signaling Pathways in Clear Cell Renal Cell Carcinoma. [PDF]

Int J Mol Sci
Glueck M, Lucaciu A, Inukollu S, Kesavan R, Janssen A, Pfeilschifter J, Subburayalu J, Krishnan RK, Vutukuri R.   +8 more
europepmc   +1 more source

Engineered immunostimulatory H2O2‐producing microreactors driven by yeast as localized living cancer therapeutics

BMEMat, EarlyView.
Engineered yeast microreactors that produce H2O2 within tumors enable selective cancer cell killing while releasing immunostimulatory components, effectively suppressing local tumor growth and activating systemic antitumor immunity, with further efficacy enhanced by anti‐PD‐1 therapy and transarterial embolization.
Wenqian He, Chunjie Wang, Minming Chen, Weihao Yang, Bin Yu, Yuhang Hu, Hengze Ding, Yifan Yan, Zhijuan Yang, Liangzhu Feng   +9 more
wiley   +1 more source

Nectin-4 expression in clear cell renal cell carcinoma

Scientific Reports
Kyra Klein, Steffen Rausch, Veronika Bahlinger, Moritz Maas, Simon Walz, Igor Tsaur, Viktoria Stühler   +6 more
doaj   +1 more source

Navigating Recurrence in Clear Cell Renal Cell Carcinoma after Adjuvant Immunotherapy. [PDF]

J Kidney Cancer VHL
Sunny G, Ravichandran S, Patnaik A, Yadav R.   +3 more
europepmc   +1 more source

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

Clinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal, Fernanda Bortolotto, Mariana Cristina Manoel, Gabriela Silveira de Araújo, Ana Carolina Fragoso Motta, Leandro Dorigan de Macedo, Lara Maria Alencar Ramos Innocentini, Joab Cabral Ramos, Isabel Schausltz Pereira Faustino   +8 more
wiley   +1 more source

Reduced <i>HMGCR</i> Expression in Clear Cell Renal Cell Carcinoma Is Associated With Poor Patient Prognosis. [PDF]

Cancer Diagn Progn
Akitaya E, Nakamura Y, Kato S, Kikuta H, Endoh T, Kuramitsu Y, Takahashi Y.   +6 more
europepmc   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma. [PDF]

BJUI Compass
Kosola S, Laajala TD, Payne I, Kukkula A, Luomala L, Mirtti T, Mattila K, Vainio P, Sundvall M, Jaakkola PM.   +9 more
europepmc   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama, Helen Kastrissios, Hossam Kadry, Daping Zhang, Salaheldin Hamed, Srinivasu Poondru, Souvik Bhattacharya, Russ Wada, Amit Garg, Yen Lin Chia   +9 more
wiley   +1 more source